论文部分内容阅读
目的检测Claudin-1蛋白在非小细胞肺癌(NSCLC)原发癌组织及其淋巴结转移癌组织中的表达,并探讨其与NSCLC各临床病理特征和预后的关系。方法利用组织芯片技术,采用免疫组织化学染色方法检测Claudin-1在1998年1月-2003年12月收集的279例NSCLC原发癌组织及其55例淋巴结转移癌组织、54例癌旁正常肺组织中的表达。运用SPSS 13.00统计软件对相关数据进行统计分析。结果 Claudin-1在279例NSCLC原发癌组织和55例淋巴结转移癌组织中的阳性表达率分别为69.9%和50.9%,在鳞癌和腺癌中的阳性表达率分别为83.7%和55.7%,在高、中分化癌组和低分化癌组中的阳性表达率分别为78.6%和62.7%。Claudin-1在原发癌组织中的阳性表达率高于其淋巴结转移癌组织(P<0.05);在鳞癌中的阳性表达率高于腺癌(P<0.05),且在高、中分化癌组中的阳性表达率高于低分化癌(P<0.05)。Claudin-1阳性表达之NSCLC患者的生存率高于阴性表达者(P<0.05)。结论 Claudin-1在NSCLC中的表达与患者的组织学类型及病理分级有关,且Claudin-1是NSCLC侵袭、转移的抑制因子,并且可能是一个有用的预后因子。
Objective To detect the expression of Claudin-1 protein in primary non-small cell lung cancer (NSCLC) and its lymph node metastasis and to investigate its relationship with clinicopathological characteristics and prognosis of NSCLC. Methods Tissue microarray technique was used to detect the expression of Claudin-1 in 279 NSCLC primary cancers and 55 cases of lymph node metastases collected from January 1998 to December 2003 by immunohistochemical staining. Expression in tissue. Using SPSS 13.00 statistical software for statistical analysis of the relevant data. Results The positive rates of Claudin-1 in 279 cases of primary NSCLC and 55 cases of lymph node metastasis were 69.9% and 50.9%, respectively. The positive rates of Claudin-1 in squamous cell carcinoma and adenocarcinoma were 83.7% and 55.7% , Respectively. The positive expression rates in high, moderately differentiated and poorly differentiated cancers were 78.6% and 62.7% respectively. The positive rate of Claudin-1 in primary cancer was higher than that in lymph node metastasis (P <0.05). The positive rate of Claudin-1 in squamous cell carcinoma was higher than that in adenocarcinoma (P <0.05) The positive rate in cancer group was higher than that in poorly differentiated cancer (P <0.05). The survival rate of Claudin-1 positive NSCLC patients was higher than that of negative patients (P <0.05). Conclusions The expression of Claudin-1 in NSCLC is related to histological type and pathological grade. Claudin-1 is an inhibitor of invasion and metastasis of NSCLC and may be a useful prognostic factor.